Update on treatment of light chain amyloidosis - Wikidata - wikimedia - TriplyDB

Update on treatment of light chain amyloidosis

Update on treatment of light chain amyloidosis

http://www.wikidata.org/entity/Q26829735

about

The Clinical Presentation and Management of Systemic Light-Chain Amyloidosis in China Evolving landscape in the management of transthyretin amyloidosis Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction Lenalidomide Desensitization in Systemic Light-Chain Amyloidosis With Multi-Organ Involvement Recurrent Pleural Effusions Occurring in Association with Primary Pulmonary Amyloidosis Bronchoscopic Diagnosis and Treatment of Primary Tracheobronchial Amyloidosis: A Retrospective Analysis from China A Tongue Lesion as a Sign of a Systemic Disease Emerging Advances in the Management of Cardiac Amyloidosis.Ocular adnexal and orbital amyloidosis: a case series and literature review.New and developing therapies for AL amyloidosis.Paraprotein-Related Kidney Disease: Glomerular Diseases Associated with Paraproteinemias.Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis.News in AL Amyloidosis ASH 2016: A rapidly evolving field of investigation.Treatment patterns and outcome following initial relapse or refractory disease in patients with systemic light chain amyloidosis.Immunoglobulin heavy light chain test quantifies clonal disease in patients with AL amyloidosis and normal serum free light chain ratio.Localized amyloidosis of the upper gingiva: a case report Clinical and prognostic utility of cardiovascular magnetic resonance imaging in myeloma patients with suspected cardiac amyloidosis.Elevation of Plasmin-α2-plasmin Inhibitor Complex Predicts the Diagnosis of Systemic AL Amyloidosis in Patients with Monoclonal Protein.Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL).Predictors of early treatment failure following initial therapy for systemic immunoglobulin light-chain amyloidosis.Primary localized tracheobronchial amyloidosis presenting with massive hemoptysis: a case report and literature review.Recurrent Syncope, a Clue in Amyloid Cardiomyopathy.Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis.The six-minute walk test in patients with AL amyloidosis: a single centre case series.Extracardiac 18F-florbetapir imaging in patients with systemic amyloidosis: more than hearts and minds.Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case–control study on 174 patients

P2860

Q26740439-D3457C19-521B-4B9F-8130-01D4DCC32783 Q28086773-9582DF31-FE5E-45D3-88EC-597917398BD3 Q28817780-5E7BA42E-9B76-4CF2-AA06-39576FDCC3A9 Q33795363-E8744245-B0DF-4A16-8C76-F7F9F94BEB35 Q36009723-3E81D3C8-1A45-4FC3-B710-64DBE5BAED47 Q36066498-AD369A3F-7B41-45B6-AD48-A86D4894F1D6 Q36280607-34642A48-4B38-4F38-ACBF-AD5447B98B08 Q36764579-F9E9A913-9D9D-4BEE-887C-A2022A594C36 Q38587648-8E4EF93A-8DAB-41A0-A7B0-F82FC0631812 Q38607031-8982EE59-24A8-420F-8440-B10817BCEA31 Q38779623-A056E1BF-2932-42FC-A1E4-84F355FAF1AA Q38831139-E9B376CA-73EE-4052-9579-901929FC2362 Q39103973-081F7059-2004-414F-88C8-C1DB93FF1A7E Q39446111-3983871C-80DE-42A4-845D-4A450E907C57 Q40287459-4B464A05-2AB3-462D-9ADC-63E9F0EF5336 Q40563598-D28D1F0F-069A-41A2-B525-58AFACB80776 Q41575087-D612E52A-D985-4620-BF94-E4A08FD1D41F Q46615830-0446B7A5-A229-46A4-BBF5-2FC3958E8304 Q47665363-FAF36016-5D38-4332-8D61-ED332B5A08CB Q47727308-74C2F540-6F75-4ADD-B076-E0814FB94471 Q48139614-116BA9BA-CBFD-494D-9FC1-43EF5BD1E2B0 Q51644510-D13407B2-A19A-4E7B-A516-F95E522A931C Q52645922-313955F1-3DFA-4760-A54C-3F9B3EB2BB7C Q52730214-A32450FD-8E62-4FEC-8311-97BBDBA779EF Q53402595-DB9FC1DE-057E-41D9-8E70-483CFBF1C988 Q55041793-0D8FAF4F-7C9E-4829-BE34-C821B62F9A99 Q58029880-632B8B90-9983-4CFC-BF5E-C186FEFC92C2

P2860

Update on treatment of light chain amyloidosis

http://www.wikidata.org/entity/Q26829735

description

2014 nî lūn-bûn

@nan

2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Update on treatment of light chain amyloidosis

@ast

Update on treatment of light chain amyloidosis

@en

Update on treatment of light chain amyloidosis

@nl

type

label

Update on treatment of light chain amyloidosis

@ast

Update on treatment of light chain amyloidosis

@en

Update on treatment of light chain amyloidosis

@nl

prefLabel

Update on treatment of light chain amyloidosis

@ast

Update on treatment of light chain amyloidosis

@en

Update on treatment of light chain amyloidosis

@nl

P1433

Q26829735-6D5666B6-C2B0-4A61-87A8-8956A7095337

P1476

Q26829735-97F653CE-3994-424A-9051-2A413E0D374B

P2093

Q26829735-502AC700-D7AE-41CA-B2C2-2DE06D50037F

Q26829735-6931DD95-621B-459A-9B14-ACB1C757E665

Q26829735-8851B156-DB65-4184-8171-F07C1B3E3838

P2860

Q26829735-012B9ED5-3250-42E7-ABF2-B50A3A89427B

Q26829735-01CC0B29-721C-42B9-9CE6-B1269246062C

Q26829735-06B1BA81-1345-4CA2-A0DD-A9EB1DDC3A65

Q26829735-0ADC3A61-1FC8-4D7D-B2A5-3C8FEF39D26D

Q26829735-1020C721-2481-4F46-B258-5B7D7075E8FA

Q26829735-1138270D-FA56-423F-ABD3-E9275A57BED2

Q26829735-126BF7EA-C7C5-4CD7-97E7-3C59D4CC4003

Q26829735-1577AA29-9DFB-4866-9C68-76DE4F654DCF

Q26829735-1681F5A0-92A0-4820-9312-D8C5CC495523

Q26829735-3375E83D-55B5-4748-B70B-2E501435EC79

P304

Q26829735-348B426F-7EA3-4C59-8879-FFD3D67735F4

P31

Q26829735-A79D91E9-CD34-4999-A69E-303FC6C892B0

P3181

Q26829735-ECBEC8C6-C0A8-4350-A0E0-7783292D2C93

P356

Q26829735-0CB5FE9B-40AF-4A88-9224-DAA8718CBCD2

P407

Q26829735-94003BAC-1336-48E0-B4DC-F684ABF8E896

P433

Q26829735-74EFC2FC-C275-4890-9FFA-7EE6F953F7F3

P478

Q26829735-41DEB729-3B0E-4296-8B92-B8C8054DBE73

P50

Q26829735-2A797237-FDEC-4523-889C-28FCCF5549FC

P577

Q26829735-DC8F0C59-0EA2-4225-B460-CB0446A49ECF

P5875

Q26829735-9B18B9D7-3482-4B79-994F-CF8C093B3FC1

P698

Q26829735-403E1F7D-7B58-434A-A636-A906D2591A6E

P932

Q26829735-6A974632-8B2C-4F5A-8F89-E34F71C2AD0E

P3181

P356

HAEMATOL.2013.087619

P1433

P1476

Update on treatment of light chain amyloidosis

@en

P2093

Ashutosh Wechalekar

http://www.w3.org/2001/XMLSchema#string

Shameem Mahmood

http://www.w3.org/2001/XMLSchema#string

Vaishali Sanchorawala

http://www.w3.org/2001/XMLSchema#string

P2860

Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis

Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis.

Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial.

Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis.

Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation.

The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis.

Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens.

Oral cyclic melphalan and dexamethasone for patients with AL amyloidosis.

Antibodies to human serum amyloid P component eliminate visceral amyloid deposits.

Radioimmunodetection of amyloid deposits in patients with AL amyloidosis.

P304

209-221

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4445633

http://www.w3.org/2001/XMLSchema#string

P356

10.3324/HAEMATOL.2013.087619

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

99

http://www.w3.org/2001/XMLSchema#string

P50

Giovanni Palladini

P577

2014-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260108183

http://www.w3.org/2001/XMLSchema#string

P698

24497558

http://www.w3.org/2001/XMLSchema#string

P932

3912950

http://www.w3.org/2001/XMLSchema#string